Premium
Response to antiseizure medications in neonates with acute symptomatic seizures
Author(s) -
Glass Hannah C.,
Soul Janet S.,
Chu Catherine J.,
Massey Shavonne L.,
Wusthoff Courtney J.,
Chang Taeun,
Cilio Maria Roberta,
Bonifacio Sonia L.,
Abend Nicholas S.,
Thomas Cameron,
Lemmon Monica,
McCulloch Charles E.,
Shellhaas Renée A.
Publication year - 2019
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/epi.14671
Subject(s) - medicine , anesthesia , refractory (planetary science) , pediatrics , etiology , encephalopathy , epilepsy , prospective cohort study , levetiracetam , physics , psychiatry , astrobiology
Summary In a prospective cohort of 534 neonates with acute symptomatic seizures, 66% had incomplete response to the initial loading dose of antiseizure medication ( ASM ). Treatment response did not differ by gestational age, sex, medication, or dose. The risk of incomplete response was highest for seizures due to intracranial hemorrhage and lowest for hypoxic‐ischemic encephalopathy, although the difference was not significant after adjusting for high seizure burden and therapeutic hypothermia treatment. Future trial design may test ASM s in neonates with all acute symptomatic seizure etiologies and could target neonates with seizures refractory to an initial ASM .